Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryOct312016	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016 SAN DIEGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2016 Financial Results on November 7, 2016 11.9 KB
Toggle SummaryOct252017	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results SAN DIEGO, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2017 Financial Results 12.2 KB
Toggle SummaryOct292018	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results SAN DIEGO , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast Read All »	View HTML
Toggle SummaryOct292019	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results SAN DIEGO , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryNov022020	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results SAN DIEGO , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryOct252021	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results SAN DIEGO , Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a Read All »	View HTML
Toggle SummaryOct242022	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results SAN DIEGO , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will Read All »	View HTML
Toggle SummaryOct252023	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results SAN DIEGO , Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to Read All »	View HTML
Toggle SummaryDec062014	Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood Expression of Genes Involved in T-cell Function and Hematopoietic Stem Cell Engraftment Significantly Increased Read All »	View HTML Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood 22.9 KB
Toggle SummaryDec212009	Fate Therapeutics' iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs San Diego, CA – Fate Therapeutics, Inc. announced today that the Company’s iPSC technology platform, developed with Sheng Ding, Ph.D., has been honored as the Top Innovation of 2009 by The Scientist and has received the 2009 North American Technology Innovation Award from Frost & Read All »	View HTML Fate Therapeutics’ iPSC Technology Awarded Top Industry Honors for Small Molecule and Protein Reprogramming Breakthroughs 12.7 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.